SAN

76.41

0%↓

UCB

249.2

-1.66%↓

SHL.DE

38.83

-0.23%↓

ARGX

612

-0.42%↓

PHIA

24.4

-0.49%↓

SAN

76.41

0%↓

UCB

249.2

-1.66%↓

SHL.DE

38.83

-0.23%↓

ARGX

612

-0.42%↓

PHIA

24.4

-0.49%↓

SAN

76.41

0%↓

UCB

249.2

-1.66%↓

SHL.DE

38.83

-0.23%↓

ARGX

612

-0.42%↓

PHIA

24.4

-0.49%↓

SAN

76.41

0%↓

UCB

249.2

-1.66%↓

SHL.DE

38.83

-0.23%↓

ARGX

612

-0.42%↓

PHIA

24.4

-0.49%↓

SAN

76.41

0%↓

UCB

249.2

-1.66%↓

SHL.DE

38.83

-0.23%↓

ARGX

612

-0.42%↓

PHIA

24.4

-0.49%↓

Kodu・Aktsiate loetelu・Nanobiotix

N
Nanobiotix

Suletud

28.8 5.3

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

28.55

Max

30.9

Põhinäitajad
By Trading Economics
Sissetulek	-5.4M
Müük	27M
Kasumimarginaal	-20.208
Töötajad	103
EBITDA	1.1M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	-16.21% downside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	1. apr 2026

Turustatistika
By TradingEconomics
Turukapital	1.6B
Eelmine avamishind	23.5
Eelmine sulgemishind	28.8

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

2.975 / 3.015 Toetus ja vastupanu

Nanobiotix Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. märts 2026, 19:08 UTC

Uudisväärsed sündmused

TotalEnergies Shutting Production in Qatar, Iraq Amid Fighting in Middle East

13. märts 2026, 18:48 UTC

Tulu

Suurimad hinnamuutused turgudel

Capricor Therapeutics Falls on Wider-Than-Expected 4Q Loss

13. märts 2026, 17:10 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: Central Bank Decisions in Focus After Jump in Energy Prices

13. märts 2026, 17:10 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: Central Bank Decisions -2-

13. märts 2026, 16:47 UTC

Uudisväärsed sündmused

The Week in Oil: Hormuz Crisis Pushes Brent Above $100

13. märts 2026, 22:27 UTC

Market Talk

Uudisväärsed sündmused

Bahrain Faces Uncertainty But Has Support Amid War, S&P Says -- Market Talk

13. märts 2026, 22:13 UTC

Market Talk

Uudisväärsed sündmused

Saudi Arabia Seen as Able to Weather Iran Conflict, S&P Says -- Market Talk

13. märts 2026, 22:04 UTC

Market Talk

Uudisväärsed sündmused

Emirate of RAK Outlook Stable Despite Iran War, S&P Says -- Market Talk

13. märts 2026, 22:00 UTC

Omandamised, ülevõtmised, äriostud

Trump Administration Set to Receive $10 Billion Fee for Brokering TikTok Deal -- WSJ

13. märts 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

13. märts 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Financial Services Roundup: Market Talk

13. märts 2026, 20:02 UTC

Market Talk

Canada Rate Hike in 2026 Would Mark 'Extraordinarily Bad' Policy -- Market Talk

13. märts 2026, 19:50 UTC

Market Talk

Uudisväärsed sündmused

Oil Posts Weekly Gains As Middle East Conflict Drags On -- Market Talk

13. märts 2026, 19:35 UTC

Uudisväärsed sündmused

Oil Prices Hover Near $100. India Asks Iran to Allow 23 Tankers Through Strait of Hormuz. -- Barrons.com

13. märts 2026, 19:00 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

13. märts 2026, 18:49 UTC

Uudisväärsed sündmused

The Iran War Could Upend AI. Here's How. -- Barrons.com

13. märts 2026, 18:24 UTC

Uudisväärsed sündmused

Impact of Middle East Conflict on TotalEnergies Activities

13. märts 2026, 18:00 UTC

Uudisväärsed sündmused

Is War Good For the Economy? -- WSJ

13. märts 2026, 17:23 UTC

Market Talk

U.S. Oil Rig Count Rises by 1 to 412 -- Market Talk

13. märts 2026, 16:46 UTC

Market Talk

Uudisväärsed sündmused

European Indexes End Week Lower as Oil Takes Driving Seat -- Market Talk

13. märts 2026, 16:38 UTC

Uudisväärsed sündmused

Higher Oil Prices Could Bring a Global Economic Shock. This Is the Number to Watch. -- Barrons.com

13. märts 2026, 16:34 UTC

Omandamised, ülevõtmised, äriostud

EQT Says It Received Around CHF21 Bln in Total From Galderma Share Sales

13. märts 2026, 16:33 UTC

Omandamised, ülevõtmised, äriostud

EQT Receives Proceeds of Around CHF1.3B From Sell-Down

13. märts 2026, 16:32 UTC

Omandamised, ülevõtmised, äriostud

EQT Completes Exit From Galderma

13. märts 2026, 16:20 UTC

Market Talk

Uudisväärsed sündmused

Financial Services Roundup: Market Talk

13. märts 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

13. märts 2026, 16:15 UTC

Uudisväärsed sündmused

Why Exxon and Energy Stocks Finally Started to Rise This Week as the Iran War Escalated -- Barrons.com

13. märts 2026, 16:11 UTC

Market Talk

Carney Tries to Put Dismal Canada Jobs Data in Context -- Market Talk

13. märts 2026, 16:00 UTC

Uudisväärsed sündmused

Here's Where the U.S. Economy Is Most Vulnerable to Iran War -- WSJ

13. märts 2026, 15:48 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Turn Higher as Supply Worries Remain -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Nanobiotix Prognoos

Hinnasiht

By TipRanks

-16.21% langus

12 kuu keskmine prognoos

Keskmine 23 EUR -16.21%

Kõrge 23 EUR

Madal 23 EUR

Põhineb 1 Wall Streeti analüütiku instrumendi Nanobiotix 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Nanobiotix aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.975 / 3.015Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.